Cambridge Investment Research Advisors
VYNT

Cambridge Investment Research Advisors’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,292
Closed -$12K – 3239
2022
Q3 		$12K Buy
+4,292
New +$16.2K ﹤0.01% 3020

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Cambridge Investment Research Advisors's VYNT Position: Q4 2022 in Review

Cambridge Investment Research Advisors sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2022, closing a stake of 4,292 shares — an estimated $12K sold.

Cambridge Investment Research Advisors first reported a position in VYNT in Q3 2022 and held it in 1 quarter. The position peaked at $12K in Q3 2022. 17 funds tracked by Wall St. Rank hold VYNT as of Q4 2022.

  • Cambridge Investment Research Advisors reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 4,292 Vyant Bio, Inc. Common Stock shares in Q4 2022, an estimated $12K.
  • Cambridge Investment Research Advisors first reported a position in Vyant Bio, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Vyant Bio, Inc. Common Stock position peaked at $12K in Q3 2022.
  • 17 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.